|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C21orf62 |
Gene summary for C21ORF62 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C21orf62 | Gene ID | 56245 |
| Gene name | chromosome 21 open reading frame 62 | |
| Gene Alias | B37 | |
| Cytomap | 21q22.11 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9NYP8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56245 | C21orf62 | S43 | Human | Liver | Cirrhotic | 2.32e-04 | -1.42e-01 | -0.0187 |
| 56245 | C21orf62 | HCC1_Meng | Human | Liver | HCC | 4.78e-05 | -1.65e-01 | 0.0246 |
| 56245 | C21orf62 | HCC2_Meng | Human | Liver | HCC | 7.37e-05 | -1.63e-01 | 0.0107 |
| 56245 | C21orf62 | HCC1 | Human | Liver | HCC | 4.50e-15 | 2.27e+00 | 0.5336 |
| 56245 | C21orf62 | HCC2 | Human | Liver | HCC | 3.45e-22 | 2.42e+00 | 0.5341 |
| 56245 | C21orf62 | HCC5 | Human | Liver | HCC | 1.49e-27 | 2.20e+00 | 0.4932 |
| 56245 | C21orf62 | Pt13.a | Human | Liver | HCC | 1.05e-05 | -1.65e-01 | 0.021 |
| 56245 | C21orf62 | Pt14.d | Human | Liver | HCC | 4.55e-02 | -1.48e-01 | 0.0143 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C21orf62 | SNV | Missense_Mutation | novel | c.84N>T | p.Lys28Asn | p.K28N | Q9NYP8 | protein_coding | tolerated(0.11) | benign(0.007) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C21orf62 | deletion | Frame_Shift_Del | novel | c.86delN | p.Asn29ThrfsTer31 | p.N29Tfs*31 | Q9NYP8 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| C21orf62 | SNV | Missense_Mutation | rs201931377 | c.266N>T | p.Ala89Val | p.A89V | Q9NYP8 | protein_coding | tolerated(1) | benign(0.03) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| C21orf62 | SNV | Missense_Mutation | rs781073580 | c.377N>A | p.Arg126His | p.R126H | Q9NYP8 | protein_coding | tolerated(0.08) | benign(0.111) | TCGA-VS-A9V3-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| C21orf62 | SNV | Missense_Mutation | rs148054755 | c.376C>T | p.Arg126Cys | p.R126C | Q9NYP8 | protein_coding | tolerated(0.08) | probably_damaging(0.979) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| C21orf62 | SNV | Missense_Mutation | rs781073580 | c.377N>A | p.Arg126His | p.R126H | Q9NYP8 | protein_coding | tolerated(0.08) | benign(0.111) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| C21orf62 | SNV | Missense_Mutation | novel | c.4G>A | p.Ala2Thr | p.A2T | Q9NYP8 | protein_coding | tolerated_low_confidence(0.28) | benign(0.065) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C21orf62 | SNV | Missense_Mutation | novel | c.38N>A | p.Ser13Asn | p.S13N | Q9NYP8 | protein_coding | deleterious(0.04) | benign(0.018) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| C21orf62 | SNV | Missense_Mutation | novel | c.148N>T | p.Arg50Trp | p.R50W | Q9NYP8 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C21orf62 | SNV | Missense_Mutation | c.626N>T | p.Ser209Ile | p.S209I | Q9NYP8 | protein_coding | tolerated(0.06) | possibly_damaging(0.908) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |